Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 14Myelodysplastic Syndromes 3Leukemia, Myeloid 2Targeted Therapy 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms by Histologic Type 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Multiple Myeloma 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1Leukemia 1Hematologic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Blast Crisis 1

Interventions

Cyclophosphamide 26fludarabine 18Dexamethasone 17pembrolizumab 12Rituximab 11Etoposide 10venetoclax 9pomalidomide 9Gemcitabine 9fludarabine phosphate 7daratumumab 7Lenalidomide 7Bortezomib 7carfilzomib 6obinutuzumab 5glofitamab 5Vincristine 5Temozolomide 5Prednisone 5Nivolumab 5Immunotherapy, Adoptive 5Cisplatin 5Calcium Dobesilate 5selinexor 4cemiplimab 4Doxorubicin 4Cytarabine 4Carboplatin 4zanubrutinib 3ruxolitinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × gilteritinib × 90 days × Clear all
NCT04988555 2026-03-24

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Sumitomo Pharma America, Inc.

Phase 1/2 Recruiting
606 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡